

CRR
JOURNAL
OF CARDIORESPIRATORY RESEARCH

ISSN 2181-0974
DOI 10.26739/2181-0974
Impact Factor SJIF 2022: 5.937

Journal of
CARDIORESPIRATORY
RESEARCH



Volume 6, Issue 2/4

2025

МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ
РЕСПУБЛИКИ УЗБЕКИСТАН

Журнал кардиореспираторных исследований

JOURNAL OF CARDIORESPIRATORY RESEARCH

Главный редактор: Э.Н.ТАШКЕНБАЕВА

Учредитель:

Самаркандский государственный
медицинский университет

Tadqiqot.uz

Ежеквартальный
научно-практический
журнал

ISSN: 2181-0974
DOI: 10.26739/2181-0974



№ 2/4
2025

Главный редактор:

Ташкенбаева Элеонора Негматовна

доктор медицинских наук, профессор, заведующая кафедрой внутренних болезней и кардиологии №2 Самаркандского Государственного медицинского университета, председатель Ассоциации терапевтов Самаркандской области.
<https://orcid.org/0000-0001-5705-4972>

Заместитель главного редактора:

Хайбулина Зарина Руслановна

доктор медицинских наук, руководитель отдела биохимии с группой микробиологии
ГУ «РСНПМЦХ им. акад. В. Вахидова» <https://orcid.org/0000-0002-9942-2910>

ЧЛЕНЫ РЕДАКЦИОННОЙ КОЛЛЕГИИ:

Аляви Анис Лютфуллаевич

академик АН РУз, доктор медицинских наук, профессор, Председатель Ассоциации Терапевтов Узбекистана, Советник директора Республиканского специализированного научно-практического центра терапии и медицинской реабилитации (Ташкент)
<https://orcid.org/0000-0002-0933-4993>

Бокерия Лео Антонович

академик РАН, доктор медицинских наук, профессор, Президент научного центра сердечно-сосудистой хирургии им. А.Н. Бакулева (Москва), <https://orcid.org/0000-0002-6180-2619>

Курбанов Равшанбек Давлетович

академик АН РУз, доктор медицинских наук, профессор, Советник директора Республиканского специализированного научно-практического медицинского центра кардиологии (Ташкент), <https://orcid.org/0000-0001-7309-2071>

Шкляев Алексей Евгеньевич

д.м.н., профессор, ректор Федерального государственного бюджетного образовательного учреждения высшего образования «Ижевская государственная медицинская академия» Министерства здравоохранения Российской Федерации

Michał Tendera

профессор кафедры кардиологии Верхнесилезского кардиологического центра, Силезский медицинский университет в Катовице, Польша (Польша)
<https://orcid.org/0000-0002-0812-6113>

Покушалов Евгений Анатольевич

доктор медицинских наук, профессор, заместитель генерального директора по науке и развитию сети клиник «Центр новых медицинских технологий» (ЦНМТ), (Новосибирск), <https://orcid.org/0000-0002-2560-5167>

Зуфаров Миржамол Мирумарович

доктор медицинских наук, профессор, руководитель отдела ГУ «РСНПМЦХ им. акад. В. Вахидова»
<https://orcid.org/0000-0003-4822-3193>

Акилов Хабибулла Атауллаевич

доктор медицинских наук, профессор, Директор Центра развития профессиональной квалификации медицинских работников (Ташкент)

Насирова Зарина Акбаровна

DSc, доцент кафедры внутренних болезней и кардиологии №2 Самаркандского Государственного Медицинского университета (ответственный секретарь) ORCID: 0000-0002-8722-0393 (ответственный секретарь)

Ризаев Жасур Алимджанович

доктор медицинских наук, профессор, Ректор Самаркандского государственного медицинского университета, <https://orcid.org/0000-0001-5468-9403>

Зиядуллаев Шухрат Худойбердиевич

доктор медицинских наук, профессор, заместитель директора по научной работе института иммунологии и геномики человека АН РУз
<https://orcid.org/0000-0002-9309-3933>

Джан Ковак

Профессор, председатель Совета Европейского общества кардиологов по инсульту, руководитель специализированной кардиологии, заведующий отделением кардиологии, кардио- и торакальной хирургии, консультант-кардиолог, больница Гленфилд, Лестер (Великобритания)

Сергио Бернардини

Профессор клинической биохимии и клинической молекулярной биологии, главный врач отдела лабораторной медицины, больница Университета Тор Вергата (Рим, Италия)

Ливерко Ирина Владимировна

доктор медицинских наук, профессор, заместитель директора по науке Республиканского специализированного научно-практического медицинского центра фтизиатрии и пульмонологии Республики Узбекистан (Ташкент)
<https://orcid.org/0000-0003-0059-9183>

Цурко Владимир Викторович

доктор медицинских наук, профессор Первого Московского государственного медицинского университета им. И.М. Сеченова (Москва)
<https://orcid.org/0000-0001-8040-3704>

Тригулова Раиса Хусановна

Доктор медицинских наук, руководитель лаборатории превентивной кардиологии, ведущий научный сотрудник лаборатории ИБС и атеросклероза. Республиканский специализированный научно-практический медицинский центр кардиологии (Ташкент)
ORCID- 0000-0003-4339-0670

Тураев Феруз Фатхуллаевич

доктор медицинских наук, Директор Республиканского специализированного научно-практического медицинского центра эндокринологии имени академика Ю.Г. Туракулова

Bosh muharrir:

Tashkenbayeva Eleonora Negmatovna

tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti 2-sonli ichki kasalliklar va kardiologiya kafedrasini mudiri, Samarqand viloyati vrachlar uyushmasi raisi
<https://orcid.org/0000-0001-5705-4972>

Bosh muharrir o'rinbosari:

Xaibulina Zarina Ruslanovna

tibbiyot fanlari doktori, "akad V. Vohidov nomidagi RIJM davlat institutining mikrobiologiya guruhi bilan biokimyo kafedrasini mudiri" <https://orcid.org/0000-0002-9942-2910>

TAHRIRIYAT A'ZOLARI:

Alyavi Anis Lyutfullayevich

O'zbekiston Respublikasi Fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, O'zbekiston Terapevtlar uyushmasi raisi, Respublika ixtisoslashtirilgan ilmiy va amaliy tibbiy terapiya markazi va tibbiy reabilitatsiya direktori maslahatchisi (Toshkent), <https://orcid.org/0000-0002-0933-4993>

Bockeria Leo Antonovich

Rossiya fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, A.N. Bakuleva nomidagi yurak-qon tomir jarrohligi ilmiy markazi prezidenti (Moskva) <https://orcid.org/0000-0002-6180-2619>

Kurbanov Ravshanbek Davlatovich

O'zbekiston Respublikasi Fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazining direktori maslahatchisi (Toshkent) <https://orcid.org/0000-0001-7309-2071>

Shklyayev Aleksey Evgenievich

Tibbiyot fanlari doktori, professor, Rossiya Federatsiyasi Sog'liqni saqlash vazirligining "Izhevsk davlat tibbiyot akademiyasi" Federal davlat byudjeti oliy ta'lim muassasasi rektori

Mixal Tendera

Katovitsadagi Sileziya Tibbiyot Universiteti, Yuqori Sileziya Kardiologiya Markazi kardiologiya kafedrasini professori (Polsha) <https://orcid.org/0000-0002-0812-6113>

Pokushalov Evgeniy Anatolevich

tibbiyot fanlari doktori, professor, "Yangi tibbiy texnologiyalar markazi" (YTTM) klinik tarmog'ining ilmiy ishlar va rivojlanish bo'yicha bosh direktorining o'rinbosari (Novosibirsk) <https://orcid.org/0000-0002-2560-5167>

Zufarov Mirjamol Mirumarovich

tibbiyot fanlari doktori, professor, "akad V. Vohidov nomidagi RIJM davlat muassasasi" bo'limi boshlig'i" <https://orcid.org/0000-0003-4822-3193>

Akilov Xabibulla Ataulayevich

tibbiyot fanlari doktori, professor, Tibbiyot xodimlarining kasbiy malakasini oshirish markazi direktori (Toshkent)

Nasirova Zarina Akbarovna

Samarqand davlat tibbiyot universiteti 2-sonli ichki kasalliklar va kardiologiya kafedrasini dotsenti, DSc (mas'ul kotib) ORCID: 0000-0002-8722-0393 (mas'ul kotib)

Rizayev Jasur Alimjanovich

tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti rektori <https://orcid.org/0000-0001-5468-9403>

Ziyadullayev Shuxrat Xudoyberdiyevich

tibbiyot fanlari doktori, professor, O'zbekiston Respublikasi Fanlar akademiyasi Immunologiya va inson genomikasi instituti ilmiy ishlar bo'yicha direktor o'rinbosari (Toshkent) <https://orcid.org/0000-0002-9309-3933>

Jan Kovak

Yevropa kardiologiya jamiyati insult kengashi raisi, 2017 yildan buyon ixtisoslashtirilgan kardiologiya kafedrasini rahbari, kardiologiya, yurak va torakal jarrohlik kafedrasini mudiri, maslahatchi kardiolog Glenfild kasalxonasi, Lester (Buyuk Britaniya)

Sergio Bernardini

Klinik biokimyo va klinik molekulyar biologiya bo'yicha professor - Laboratoriya tibbiyoti bo'limi bosh shifokori – Tor Vergata universiteti kasalxonasi (Rim-Italiya)

Liverko Irina Vladimirovna

tibbiyot fanlari doktori, professor, Respublika ixtisoslashtirilgan fiziologiya va pulmonologiya ilmiy-amaliy tibbiyot markazining ilmiy ishlar bo'yicha direktor o'rinbosari (Toshkent) <https://orcid.org/0000-0003-0059-9183>

Surko Vladimir Viktorovich

tibbiyot fanlari doktori, professori I.M. Sechenov nomidagi Birinchi Moskva Davlat tibbiyot universiteti (Moskva) <https://orcid.org/0000-0001-8040-3704>

Trigulova Raisa Xusainovna

Tibbiyot fanlari doktori, Profilaktik kardiologiya laboratoriyasi mudiri, YuIK va ateroskleroz laboratoriyasining yetakchi ilmiy xodimi. Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi (Toshkent) ORCID- 0000-0003-4339-0670

Turayev Feruz Fatxullayevich

tibbiyot fanlari doktori, akademik Y.X.To'raqulov nomidagi Respublika ixtisoslashtirilgan endokrinologiya ilmiy amaliy tibbiyot markazi direktori <https://orcid.org/0000-0002-1321-4732>

Chief Editor:

Tashkenbaeva Eleonora Negmatovna

Doctor of Medical Sciences, professor, Head of the Department of Internal Diseases and cardiology No. 2 of the Samarkand State Medical University, Chairman of the Association of Physicians of the Samarkand Region. <https://orcid.org/0000-0001-5705-4972>

Deputy Chief Editor:

Xaibulina Zarina Ruslanovna

Doctor of Medical Sciences, Head of the Department of Biochemistry with the Microbiology Group of the State Institution "RSSC named after acad. V. Vakhidov", <https://orcid.org/0000-0002-9942-2910>

MEMBERS OF THE EDITORIAL BOARD:

Alyavi Anis Lutfullaevich

Academician of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor, Chairman of the Association of Physicians of Uzbekistan, Advisor to the Director of the Republican Specialized Scientific - Practical Center of Therapy and Medical Rehabilitation (Tashkent) <https://orcid.org/0000-0002-0933-4993>

Bockeria Leo Antonovich

Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, President of the Scientific Center for Cardiovascular Surgery named after A.N. Bakuleva (Moscow) <https://orcid.org/0000-0002-6180-2619>

Kurbanov Ravshanbek Davletovich

Academician of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor, Advisor to the Director Republican Specialized Scientific and Practical Medical Center of Cardiology, (Tashkent) <https://orcid.org/0000-0001-7309-2071>

Shklyayev Aleksey Evgenievich

Doctor of Medical Sciences, Professor, Rector of the Federal State Budgetary Educational Institution of Higher Education "Izhevsk State Medical Academy" of the Ministry of Health of the Russian Federation

Michal Tendera

Professor of the Department of Cardiology, Upper Silesian Cardiology Center, Silesian Medical University in Katowice, Poland (Poland) <https://orcid.org/0000-0002-0812-6113>

Pokushalov Evgeny Anatolyevich

Doctor of Medical Sciences, Professor, Deputy Director General for Science and Development of the Clinic Network "Center for New Medical Technologies" (CNMT), (Novosibirsk) <https://orcid.org/0000-0002-2560-5167>

Akilov Xabibulla Ataulaevich

Doctor of Medical Sciences, Professor, Center for the development of professional qualifications of medical workers (Tashkent)

Nasyrova Zarina Akbarovna

DSc, Associate Professor of the Department of Internal Diseases and cardiology No. 2 of the Samarkand State Medical University (Executive Secretary) ORCID: 0000-0002-8722-0393 (Executive Secretary)

Rizaev Jasur Alimjanovich

Doctor of Medical Sciences, Professor, Rector of the Samarkand State Medical University <https://orcid.org/0000-0001-5468-9403>

Ziyadullaev Shuhrat Khudoyberdievich

Doctor of Medical Sciences, Professor, Deputy Director for Scientific Work of the Institute of Human Genomics Immunology of the Academy of Sciences of the Republic of Uzbekistan. <https://orcid.org/0000-0002-9309-3933>

Jan Kovac

Professor Chairman, European Society of Cardiology Council for Stroke, Lead of Specialised Cardiology, Head of Cardiology, Cardiac and Thoracic Surgery, Consultant Cardiologist, Glenfield Hospital, Leicester (United Kingdom)

Sergio Bernardini

Full Professor in Clinical Biochemistry and Clinical Molecular Biology -Head Physician of the Laboratory Medicine Unit- University of Tor Vergata Hospital (Rome-Italy)

Liverko Irina Vladimirovna

Doctor of Medical Sciences, Professor, Deputy Director for Science of the Republican Specialized Scientific and Practical Medical Center for Phthiology and Pulmonology of the Republic of Uzbekistan (Tashkent) <https://orcid.org/0000-0003-0059-9183>

Zufarov Mirjamol Mirumarovich

Doctor of Medical Sciences, Professor, Head of the Department of the State Institution "RSNPMTSH named after acad. V. Vakhidov" <https://orcid.org/0000-0003-4822-3193>

Tsurko Vladimir Viktorovich

Doctor of Medical Sciences, professor Of Moscow State Medical University by name I.M. Sechenov (Moscow) <https://orcid.org/0000-0001-8040-3704>

Trigulova Raisa Khusainovna

Doctor of Medical Sciences, Head of the Laboratory of Preventive Cardiology, Leading Researcher of the Laboratory of IHD and Atherosclerosis. Republican Specialized Scientific and Practical Medical Center of Cardiology (Tashkent) ORCID- 0000-0003-4339-0670

Turaev Feruz Fatxullaevich

Doctor of Medical Sciences, Director of the Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Yu.G. Turakulova

Алимов Дониёр Анварович
доктор медицинских наук, директор
Республиканского научного центра
экстренной медицинской помощи

Янгиев Бахтиёр Ахмедович
кандидат медицинских наук,
директор Самаркандского филиала
Республиканского научного центра
экстренной медицинской помощи

Абдуллаев Акбар Хатамович
доктор медицинских наук, главный
научный сотрудник Республиканского
специализированного научно-
практического центра медицинской
терапии и реабилитации
<https://orcid.org/0000-0002-1766-4458>

Агабабян Ирина Рубеновна
кандидат медицинских наук, доцент,
заведующая кафедрой терапии ФПДО,
Самаркандского Государственного
медицинского института

Алиева Нигора Рустамовна
доктор медицинских наук, заведующая
кафедрой Госпитальной педиатрии №1
с основами нетрадиционной медицины
ТашПМИ

Исмаилова Адолат Абдурахимовна
доктор медицинских наук, профессор,
заведующая лабораторией
фундаментальной иммунологии
Института иммунологии геномики
человека АН РУз

Камалов Зайнитдин Сайфутдинович
доктор медицинских наук, профессор,
заведующий лабораторией
иммунорегуляции Института
иммунологии и геномики
человека АН РУз

Каюмов Улугбек Каримович
доктор медицинских наук, профессор,
заведующий кафедрой внутренних
болезней и телемедицины Центра
развития профессиональной
квалификации медицинских работников

Хусинова Шоира Акбаровна
кандидат философских наук, доцент,
заведующая кафедрой общей практики,
семейной медицины ФПДО
Самаркандского Государственного
медицинского института

Шодиккулова Гуландом Зикрияевна
д.м.н., профессор, заведующая
кафедрой внутренних болезней № 3
Самаркандского Государственного
Медицинского Института
(Самарканд)
<https://orcid.org/0000-0003-2679-1296>

Alimov Doniyor Anvarovich
*tibbiyot fanlari doktori, Respublika
shoshilinch tibbiy yordam ilmiy
markazi direktori (Toshkent)*

Yangiyev Baxtiyor Axmedovich
*tibbiyot fanlari nomzodi,
Respublika shoshilinch tibbiy
yordam ilmiy markazining
Samarqand filiali direktori*

Abdullayev Akbar Xatamovich
*tibbiyot fanlari doktori, O'zbekiston
Respublikasi Sog'liqni saqlash
vazirligining "Respublika
ixtisoslashtirilgan terapiya va tibbiy
reabilitatsiya ilmiy-amaliy
tibbiyot markazi" davlat
muassasasi bosh ilmiy xodimi
<https://orcid.org/0000-0002-1766-4458>*

Agababayan Irina Rubenovna
*tibbiyot fanlari nomzodi, dotsent,
DKTF, terapiya kafedrasini mudiri,
Samarqand davlat tibbiyot instituti*

Alieva Nigora Rustamovna
*tibbiyot fanlari doktori, 1-sonli
gospital pediatriya kafedrasini mudiri,
ToshPTI*

Ismoilova Adolat Abduraximovna
*tibbiyot fanlari doktori, professor,
O'zbekiston Respublikasi Fanlar
akademiyasining Odam genomikasi
immunologiyasi institutining
fundamental immunologiya
laboratoriyasining mudiri*

Kamalov Zaynitdin Sayfutdinovich
*tibbiyot fanlari doktori, professor,
O'zbekiston Respublikasi Fanlar
akademiyasining Immunologiya va
inson genomikasi institutining
Immunogenetika laboratoriyasi mudiri*

Qayumov Ulug'bek Karimovich
*tibbiyot fanlari doktori, professor,
Tibbiyot xodimlarining kasbiy
malakasini oshirish markazi, ichki
kasalliklar va teletibbiyot kafedrasini
mudiri (Toshkent)*

Xusinova Shoira Akbarovna
*tibbiyot fanlari nomzodi, dotsent,
Samarqand davlat tibbiyot instituti
DKTF Umumiy amaliyot va oilaviy
tibbiyot kafedrasini mudiri (Samarqand)*

Shodikulova Gulandom Zikriyevna
*tibbiyot fanlari doktori, professor,
Samarqand davlat tibbiyot instituti 3-
ichki kasalliklar kafedrasini mudiri
(Samarqand)
<https://orcid.org/0000-0003-2679-1296>*

Alimov Doniyor Anvarovich
*Doctor of Medical Sciences, Director of
the Republican Scientific Center of
Emergency Medical Care*

Yangiev Bakhtiyor Axmedovich
*PhD, Director of Samarkand branch of
the Republican Scientific Center of
Emergency Medical Care*

Abdullaev Akbar Xatamovich
*Doctor of Medical Sciences,
Chief Researcher of the State Institution
"Republican Specialized Scientific and
Practical Medical Center for Therapy and
Medical Rehabilitation" of the Ministry of
Health of the Republic of Uzbekistan,
<https://orcid.org/0000-0002-1766-4458>*

Agababayan Irina Rubenovna
*PhD, Associate Professor, Head of the
Department of Therapy, FAGE,
Samarkand State Medical Institute*

Alieva Nigora Rustamovna
*Doctor of Medical Sciences, Head of the
Department of Hospital Pediatrics
No. 1 with the basics of alternative
medicine, TashPMI*

Ismailova Adolat Abduraximovna
*doctor of Medical Sciences, Professor,
Head of the Laboratory of Fundamental
Immunology of the Institute of
Immunology of Human
Genomics of the Academy of Sciences
of the Republic of Uzbekistan*

Kamalov Zainitdin Sayfutdinovich
*doctor of Medical Sciences, Professor,
Head of the Laboratory of
Immunogenetics of the Institute of
Immunology and Human Genomics
of the Academy of Sciences of the
Republic of Uzbekistan*

Kayumov Ulugbek Karimovich
*Doctor of Medical Sciences, Professor,
Head of the Department of Internal
Diseases and Telemedicine of the Center
for the development of professional
qualifications
of medical workers*

Khusinova Shoira Akbarovna
*PhD, Associate Professor, Head of the
Department of General Practice,
Family Medicine FAGE of the
Samarkand State Medical Institute*

Shodikulova Gulandom Zikriyevna
*Doctor of Medical Sciences, professor,
head of the Department of Internal
Diseases N 3 of Samarkand state medical
institute (Samarkand)
<https://orcid.org/0000-0003-2679-1296>*

Халиков Каххор Мирзаевич
кандидат медицинских наук, доцент
заведующий кафедрой биологической
химии Самаркандского
государственного медицинского
университета

Аннаев Музаффар
Ассистент кафедры внутренних
болезней и кардиологии №2
Самаркандского государственного
медицинского университета
(технический секретарь)

Тулабаева Гавхар Миракбаровна
Заведующая кафедрой кардиологии,
Центр развития профессиональной
квалификации медицинских
работников, д.м.н., профессор

**Абдумаджидов Хамидулла
Амануллаевич**
Бухарский государственный
медицинский институт имени Абу
Али ибн Сино. Кафедра «Хирургические
болезни и реанимация». Доктор
медицинских наук, профессор.

Саидов Максуд Арифович
к.м.н., директор Самаркандского
областного отделения
Республиканского специализированного
научно-практического медицинского
центра кардиологии (г. Самарканд)

Срождинова Нигора Зайнутдиновна
д.м.н. Заведующая научно-
исследовательской лабораторией
кардиодиабета и метаболических
нарушений РСНПМЦК

Xalikov Qaxxor Mirzayevich
Tibbiyot fanlari nomzodi, dotsent
Samarqand davlat tibbiyot universiteti
Biologik kimyo kafedrasini mudiri

Annayev Muzaffar G'iyos o'g'li
Samarqand davlat tibbiyot universiteti 2-son
ichki kasalliklar va kardiologiya kafedrasini
assistenti (texnik kotib)

Tulabayeva Gavxar Mirakbarovna
kardiologiya kafedrasini mudiri, tibbiyot
xodimlarining kasbiy malakasini rivojlantirish
markazi, tibbiyot fanlari doktori, professor

Abdumadjidov Xamidulla Amanullayevich
«Abu Ali ibn Sino nomidagi Buxoro davlat
tibbiyot oliygohi» Xirurgiya kasalliklari va
reanimatsiya kafedrasini proffessori, tibbiyot
fanlari doktori.

Saidov Maqsud Arifovich
tibbiyot fanlari nomzodi,
Respublika ixtisoslashgan kardialogiya
ilmiy amaliy tibbiyot markazi Samarqand
viloyat mintaqaviy filiali direktori
(Samarqand)

Srojidinova Nigora Zaynutdinovna
t.f.d. Kardiodiabet va metabolik buzilishlar
ilmiy tadqiqot laboratoriyasi mudiri

Khalikov Kakhor Mirzayevich
Candidate of Medical Sciences,
Associate Professor, Head of the Department
of Biological Chemistry, Samarkand State
Medical University

Annaev Muzaffar
Assistant of the Department of Internal
Diseases and Cardiology No. 2 of the
Samarkand State Medical University
(technical secretary)

Tulabayeva Gavkhar Mirakbarovna
Head of the Department of Cardiology,
Development Center professional
qualification of medical workers,
MD, professor

**Abdumadjidov Khamidulla
Amanullayevich**
“Bukhara state medical institute named
after Abu Ali ibn Sino”. DSc, professor.

Saidov Maksud Arifovich
Candidate of Medical Sciences, Director
of the Samarkand Regional Department of
the Republican Specialized Scientific and
Practical Medical Center of Cardiology
(Samarkand)

Srojidinova Nigora Zaynutdinovna
DSc, Head of Cardiodiabetes and Metabolic
Disorders Laboratory

1	Агабабян И.Р., Низамова Н.Г Влияние терапии сакубитрил-валсартаном на пациентов с сердечной недостаточностью с сохранённой фракцией выброса I.R. Agababyan, N.G. Nizamova The impact of Sacubitril-Valsartan Therapy in Patients with Heart Failure with Preserved Ejection Fraction I.R. Agababyan, N.G. Nizamova Saqlangan haydash fraksiyasi bilan yurak yetishmovchiligida sakubitril-valsartan terapiyasining ta'siri.....	10
2	Алланазаров А.Б. Комплексное лечение острого обструктивного бронхита у часто болеющих детей Allanazarov A.B. Complex treatment of acute obstructive bronchitis in frequently ill children Allanazarov A.B. Tez-tez kasal bo'lgan bolalarda o'tkir obstruktiv bronxitni kompleks davolash.....	16
3	Т.У. Арипова, Г.Ш. Негматова. З.Ю. Халимова Ранние молекулярные и иммунные маркеры как основа для дифференцированной терапии аутоиммунного полигланулярного синдрома 2 типа (обзор литературы) T.U. Aripova, G.Sh.Negmatova. Z.Y. Xalimova Early molecular and immune markers as a basis for differentiated therapy of type 2 autoimmune polyglandular syndrome (literature review) T.U. Aripova, G.Sh.Negmatova. Z.Y. Xalimova 2-tur avtoimmun poliglandular sindromi uchun erta molekulyar va immun belgilar – differensiallashtirilgan terapiyaning asosi (adabiyotlar sharhi).....	19
4	Дж.З.Бердикулов, В.Н.Туракулов Укрепление общественного здоровья: методы и подходы J.Z.Berdikulov, V.N.Turakulov Strengthening Public Health: Methods and Approaches J.Z.Berdikulov, V.N.Turakulov Aholi salomatligini mustahkamlash: usullar va yondashuvlar.....	23
5	Н.М. Джаббарова, И.Р. Агабабян Эффективность ингибиторов натрий-глюкозного котранспортера 2 типа у больных с неалкогольной жировой болезнью печени на фоне инсулинорезистентности N.M. Jabbarova, I.R. Agababyan Effectiveness of type 2 sodium-glucose cotransporter inhibitors in patients with nonalcoholic fatty liver disease against the background of insulin resistance N.M. Djabbarova, I.R. Agababyan Insulin qarshiligi bilan bog'liq noalkogol yog'li jigar kasalligi bo'lgan bemorlarda natriy-glyukoza kotransportyor 2-turi ingibitorlarining samaradorligi.....	26
6	Г.А. Закирова, Д.Р. Машарипова, Р.Х. Мирзаев, Ш.Р. Ибабекова Особенности дисфункции почек у пациентов с хронической сердечной недостаточностью G.A. Zakirova, D.R. Masharipova, R.Kh. Mirzaev, Sh.R. Ibabekova Characteristics of renal dysfunction in patients with chronic heart failure Г.А. Закирова, Д.Р. Машарипова, Р.Х. Мирзаев, Ш.Р. Ибабекова Surunkali yurak yetishmovchiligi bilan kasallangan bemorlarda buyraklar disfunktsiyasining xususiyatlari.....	30
7	Ибрагимова М.Ф., Жамshedова С.Ж. Влияние микробиоты кишечника на течение и исход обструктивного бронхита у часто-болеющих детей Ibragimova M.F., Zhamshedova S.Zh. Influence of intestinal microbiota on the course and outcome of obstructive bronchitis in frequently sick children Ibragimova M. F., Jamshedova S.J. Ichak mikrobiotasining tez-tez kasal bo'lgan bolalarda obstruktiv bronxit kechishiga va natijalariga ta'siri.....	41
8	S.N.Kurbanova Samarqand viloyati aholisi orasida yod tanqisligida KAP ko'rsatgichini o'rganish va ularning siydikdagi yod konsentratsiyasi bilan bog'liqligini tahlil qilish S.N.Kurbanova Изучение показателей ЦАП при дефиците йода у населения самаркандской области и анализ их связи с концентрацией йода в моче S.N.Kurbanova Study of the KAP indicators in iodine deficiency among the population of Samarkand region and analysis of their relationship with urine iodine concentration.....	45
9	Г. Т. Маджидова., У.Т.Намозов Иммунологические особенности хронической обструктивной болезни легких и его сочетания с COVID-19 G.T.Madjidova., U.T. Namozov Immunological features of chronic obstructive pulmonary disease and its combination with COVID-19 G.T.Madjidova, Namozov U.T O'pkaning surunkali obstruktiv kasalligi va uning covid-19 bilan immunologik xususiyatlari.....	52
10	И.К. Мамаризаев, М.Ф. Ибрагимова	

	Кардиоваскулярные и респираторные нарушения у новорожденных родившихся от матерей с эндотоксикозом I.K. Mamarizaev, M.F. Ibragimova Evaluation of the effectiveness of pentoxifylline in the treatment of community-acquired pneumonia accompanied by myocarditis in children I.K. Mamarizaev, M.F. Ibragimova Bolalarda miokardit bilan kechuvchi shifoxonadan tashqari pnevmoniyada pentoksifillin samaradorligini baxolash.....	57
11	Н.Т.Маматова, К.У.Куйлиев, З.Х.Жумаев, А.А.Ашуров, Б.А.Абдухакимов, Ф.К.Уринов Депрессивные расстройства у впервые выявленных больных туберкулезом N.T.Mamatova, K.U.Kuyliyev, Z.X.Jumayev, A.A.Ashurov, B.A.Abdukhakimov, F.K.Urinov Depressive disorders in newly diagnosed tuberculosis patients N.T.Mamatova, K.U.Kuyliyev, Z.X.Jumayev, A.A.Ashurov, B.A.Abduhakimov, F.K.Urinov Birinchi marta aniqlangan sil kasalligi bilan og'riqan bemorlarda depressiv buzilishlar.....	63
12	Г.Ш. Негматова, А.Д.Давранова Нарушения менструальной функции при заболеваниях щитовидной железы G.Sh.Negmatova, A.D. Davranova Menstrual disorders in thyroid diseases G.Sh.Negmatova, A.D. Davranova Qalqonsimon bez kasalliklarda hayz siklining buzilishi.....	68
13	Ташбаев Н.А., Калдыгозова Г.Е., Абдумаджидов Х.А. Характеристика больных неспецифическим и специфическим заболеванием среднего уха при туберкулезе легких Tashbayev N.A., Kaldygozova G.E., Abdumajidov Kh.A. Characteristics of patients with nonspecific and specific diseases of the middle ear in pulmonary tuberculosis Tashbayev N.A., Kaldygozova G.E., Abdumajidov X.A. O'pka sili bilan kasallangan bemorlarda o'rta quloqning nospetsifik va spetsifik kasalliklari tavsifi.....	72
14	И.Э. Уралбоев, Х.Н. Шадиева Метод консервативной коррекции килевидной деформации грудной клетки у девушек в пубертатном и постпубертатном периодах жизни I.E. Uralboev, Kh.N. Shadieva Method of the conservative correction of Pectus carinatum in girls of pubertal and postpubertal periods of life I.E. Uralboyev, X.N. Shadiyeva Balog'at yoshi va balog'at yoshidan keyingi qizlarda ko'krak qafasining kilsimon deformatsiyasi korrektsiyasini konservativ usuli.....	76
15	З.Ю.Халимова, Г.Дж. Наримова, С.Ш.Курбанова, М.Х.Аблакулова Взаимодействие мелатонина и метаболических параметров у женщин с ожирением: клинический анализ Z.Y. Halimova, G.J. Narimova, S.Sh. Kurbanova, M.H. Ablakulova Interaction of melatonin and metabolic parameters in obese women: case analysis Z.Y.Halimova, G.J.Narimova, S.Sh.Kurbanova, M.X.Ablakulova Semirib ketgan ayollarda melatonin va metabolik parametrlarning o'zaro ta'siri: klinik tahlil.....	81
16	А.О.Холикова, Д.Х.Абидова Оценка качества жизни пациентов с акромегалией и вторичным синдромом «пустого» турецкого седла с помощью международного опросника Acro-Qol A.O.Kholikova, D.Kh.Abidova Assessment of the quality of life of patients with acromegaly and secondary syndrome of the "empty" Turkish saddle using the Acro-Col international questionnaire A.O.Xoliquova, D.X.Abidova Acro-Qol xalqaro so'rovnoma dan foydalanib, akromegalya va "bo'sh" turk egarining akromegaly va ikkilamchi sindromi bo'lgan bemorlarning hayot sifatini baholash.....	87
17	Х.Н. Шадиева Клинический случай рестриктивной кардиомиопатии у мальчика Kh.N. Shadieva Clinical case of restrictive cardiomyopathy in boy X.N. Shadiyeva O'g'il bolada restriktiv kardiomiopatiyaning klinik holi.....	91
18	С.Т.Ярматов, Н.А.Вафоева Оптимизация лечения и медицинской реабилитации при сопутствующих заболеваниях сердечно – сосудистой системы S.T.Yarmatov, N.A.Vafoyeva Cardiovascular system diseases treatment in comorbid course and optimization of medical rehabilitation S.T.Yarmatov, N.A.Vafoyeva Yurak – qon tomir tizimi kasalliklari komorbid kechishida davolash va tibbiy reabilitatsiyani optimallashtirish.....	94



Агабабян И.Р.

к.м.н., профессор, Самаркандский государственный
медицинский университет
Самарканд, Узбекистан

Низамова Н.Г.

Базовый докторант, Самаркандский государственный
медицинский университет
Самарканд, Узбекистан

ВЛИЯНИЕ ТЕРАПИИ САКУБИТРИЛ-ВАЛСАРТАНОМ НА ПАЦИЕНТОВ С СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ С СОХРАНЁННОЙ ФРАКЦИЕЙ ВЫБРОСА

For citation: I.R. Agababyan, N.G. Nizamova. THE IMPACT OF SACUBITRIL-VALSARTAN THERAPY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION. Journal of cardiorespiratory research. 2025, vol 6, issue 2/4, pp.

 <http://dx.doi.org/10.26739/2181-0974/2025/6/2/4/1>

АННОТАЦИЯ

Актуальность: За последние 20 лет во всём мире количество случаев сердечной недостаточности удвоилось. Сердечная недостаточность с сохранённой фракцией выброса (ХСНсФВ) — это заболевание, которое встречается всё чаще, и его масштабы становятся настоящей проблемой для здравоохранения. Эффективных методов лечения для этой болезни пока не существует, что делает её особенно важной для изучения. **Материалы и методы:** Исследование было проведено в кардиологическом центре Самаркандской области. Оно представляло собой проспективное наблюдательное исследование, в котором приняли участие 48 пациентов с хронической сердечной недостаточностью с сохранённой фракцией выброса (ХСНсФВ). Сравнивались ключевые клинические и лабораторные показатели пациентов до и после лечения. Статистическая обработка данных выполнялась с использованием программы SPSS версии 28.0, различия считались статистически значимыми при уровне $p < 0,05$. **Результаты:** Пациенты были разделены на две группы: 1-я группа ($n=24$): получала терапию сакубутрилом/валсартаном. 2-я группа ($n=24$): получала терапию только валсартаном. Через 16 недель терапии было зафиксировано значительное улучшение клинических и лабораторных показателей у пациентов, получавших сакубутрил/валсартан: Среднее снижение систолического артериального давления (САД) составило $-10,3 \pm 1,0$ мм рт. ст. в группе сакубутрил/валсартана против $-6,4 \pm 0,9$ мм рт. ст. в группе валсартана ($p < 0,05$). Улучшение функционального класса ХСН по NYHA наблюдалось у 63% пациентов первой группы против 42% во второй группе ($p < 0,05$). **Выводы:** Полученные результаты подтверждают, что комбинированная терапия сакубутрилом/валсартаном эффективнее монотерапии валсартаном у пациентов с ХСНсФВ. Лечение сакубутрилом/валсартаном способствовало значительному снижению артериального давления и частоты госпитализаций, а также улучшению функционального состояния пациентов. Это позволяет рассматривать данную терапию как перспективное направление в лечении пациентов с ХСНсФВ, особенно в случаях резистентной гипертензии.

Ключевые слова: Сердечная недостаточность с сохранённой фракцией выброса (ХСНсФВ), сакубутрил, валсартан, NYHA, систолического артериального давления (САД)

I.R. Agababyan

Doctor of Medicine, Professor, Samarkand State Medical University
Samarkand, Uzbekistan

N.G. Nizamova

PhD student, Samarkand State Medical University
Samarkand, Uzbekistan

THE IMPACT OF SACUBITRIL-VALSARTAN THERAPY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION

ANNOTATION

Background: Over the past two decades, the number of heart failure cases has doubled worldwide, and heart failure with preserved ejection fraction (HFpEF) is becoming increasingly common, posing a significant challenge to public health. Currently, there are no effective treatments for this condition, making it crucial to conduct research. **Materials and Methods:** This study was conducted at the Cardiological centre of Samarkand region. It was an observational study that included 48 patients diagnosed with chronic HFpEF. Key clinical and laboratory parameters were recorded before and after treatment, and statistical analysis was performed using SPSS version 28.0. Differences were considered significant if $p < 0.05$. **Results:** The patients were divided into two groups: Group 1 ($n=24$) received sacubutril/valsartan therapy, and Group 2 ($n=24$) received valsartan

monotherapy. After 16 weeks of treatment, a significant improvement in clinical and laboratory parameters was noted in patients receiving sacubutril/valsartan. The average decrease in systolic blood pressure (BP) was -10.3 ± 1.0 mmHg in the sacubutril/valsartan group compared to -6.4 ± 0.9 mmHg in the valsartan-only group ($p < 0.05$). Functional class improvement of CHF (Congestive Heart Failure) according to the NYHA (New York Heart Association) classification was observed in 63% of patients in Group 1 versus 42% in Group 2 ($p < 0.05$). **Conclusions:** These results confirm that sacubutril/valsartan combination therapy is more effective than valsartan monotherapy in patients with congestive heart failure. Treatment with sacubutril/valsartan has shown significant reductions in blood pressure, and hospitalization rates, as well as improvements in the functional status of patients. These findings suggest that this therapy could be a promising approach for treating patients with chronic heart failure, especially those with resistant hypertension.

Key words: Heart failure with preserved ejection fraction (HFpEF), sacubutril, valsartan, New York Heart Association (NYHA), systolic blood pressure (SBP)

Agababyan I.R.

t.f.n., professor, Samarqand davlat tibbiyot instituti

Samarqand, O'zbekiston

Nizamova N.G.

Tayanch doktorant, Samarqand davlat tibbiyot instituti

Samarqand, O'zbekiston

SAQLANGAN HAYDASH FRAKSIYASI BILAN YURAK YETISHMOVCHILIGIDA SAKUBITRIL-VALSARTAN TERAPIYASINING TA'SIRI

ANNOTATSIYA

Dolzarbli: So'nggi 20 yil ichida yurak yetishmovchiligi holatlari soni dunyo bo'ylab ikki baravar oshganligi qayd qilingan. Saqlangan qon haydash fraksiyasi bilan yurak yetishmovchiligi (SQHFSYuY) keng tarqalgan kasallik bo'lib, uning ko'lami aholi salomatligi uchun haqiqiy muammoga aylanib bormoqda. Ushbu kasallikni samarali davolash usullari hali mavjud yemas, bu esa uni o'rganishni dolzarb muammoligini tasdiqlaydi. **Materiallar va usullar:** Tadqiqot ishi Samarqand viloyati kardiologiya markazida o'tkazildi. Tadqiqot saqlangan qon haydash fraksiyasi bilan yurak yetishmovchiligi (SQHFSYuY) aniqlangan 48 bemorni o'z ichiga olgan bo'lib, davolanishdan oldin va keyin bemorlarning asosiy klinik va laboratoriya ko'rsatkichlari taqqoslandi. Statistik ma'lumotlarni qayta ishlash SPSS dasturi 28.0 versiyasi yordamida amalga oshirildi, ko'rsatkichlar farqi $P < 0.05$ darajasida statistik jihatdan ahamiyatli hisoblandi. **Natijalar:** Tadqiqotga kiritilgan bemorlar ikki guruhga ajratildi: 1-guruh ($n=24$): sakubitril/valsartan berildi. 2-guruh ($n=24$): faqat valsartan bilan davolash olib borildi. 16 haftalik davodan so'ng sakubitril/ valsartan olgan bemorlarda klinik va laboratoriya parametrlarining sezilarli yaxshilanishi qayd etildi: sistolik qon bosimining (SQB) o'rtacha pasayishi sakubitril/ valsartan guruhida -10.3 ± 1.0 mm.sim.ust, valsartan guruhida -6.4 ± 0.9 mm.sim.ust ni tashkil etdi ($P < 0,05$). NYHA bo'yicha YuYe funksional sinfining yaxshilanishi birinchi guruhdagi bemorlarning 63 foizida, ikkinchi guruhdagi 42% ($P < 0.05$) da kuzatilgan. **Xulosa:** Olingan natijalar SYuYe mavjud bemorlarda sakubitril/ valsartan bilan kompleks terapiya valsartan bilan monoterapiyaga qaraganda samaraliroq ekanligini tasdiqlaydi. Sakubitril/ valsartan bilan davolash qon bosimini va gospitalizatsiya qilish chastotasini sezilarli darajada kamaytirdi, shuningdek bemorlarning funksional holatini yaxshiladi. Bu bizga ushbu terapiyani SYuYe bilan og'rigan bemorlarni davolashda, ayniqsa gipotenziv vositalarga rezistentlik kuzatilgan gipertenziya holatlarida samarali davo usuli sifatida qo'llashga imkon beradi.

Kalit so'zlar: Saqlangan qon haydash fraksiyasi bilan yurak yetishmovchiligi (SQHFSYuY), sakubitril, valsartan, NYHA, sistolik qon bosimi (SQB).

Introduction

The relationship between arterial hypertension and heart failure with preserved ejection fraction (HFpEF) is well established, with left ventricular hypertrophy, arterial stiffness, and renal insufficiency likely contributing to the development of this syndrome [10]. Heart failure (HF) with preserved ejection fraction (pEF), also known as diastolic HF, is typically defined as an ejection fraction (EF) greater than 50% according to criteria established by the European Society of Cardiology [7]. HFpEF accounts for approximately half of all HF cases and is associated with significant morbidity and mortality [4]. Cheng and colleagues demonstrated that post-discharge, HFpEF patients experience a high rate of rehospitalization: 20% within 30 days and over 50% within a year. Despite the poor prognosis, there are no effective pharmacological treatments for HF except for diuretics, which significantly distinguishes it from HF with reduced EF [1]. HF is a heterogeneous clinical syndrome that can be caused by various etiological factors, including aging, obesity, ischemic heart disease, diabetes, hypertension, and impaired renal function [11].

Recent clinical trials, including the PARADIGM-HF study, have shown that a novel drug, LCZ696, an angiotensin receptor-neprilysin inhibitor (ARNI), is superior to enalapril in reducing the risk of mortality and hospitalization in patients with HF and high heart rate (HR) [6]. Notably, subgroup analysis also revealed that sacubitril-valsartan leads to a slower decline in glomerular filtration rate (GFR) in patients with chronic kidney disease (CKD) and HF. However, the impact of sacubitril-valsartan on HR remains controversial [2]. The PARAMOUNT-HF study demonstrated that ARNI effectively reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, significantly decreases left atrial size, and improves the New York Heart Association (NYHA) functional class to a greater extent than valsartan [8].

Emerging research underscores the pivotal role of endothelial dysfunction in the development of heart failure with preserved ejection fraction (HFpEF). Patients with HFpEF exhibit reduced cardiac microvascular density and systemic endothelial impairment, contributing to disease progression [13].

Additionally, metabolic disturbances and chronic inflammation are significant contributors to HFpEF pathogenesis. Conditions such as type 2 diabetes and obesity are linked to myocardial remodeling and fibrosis, exacerbating diastolic dysfunction [14].

These insights suggest that therapeutic strategies targeting endothelial function, metabolic health, and inflammatory pathways may offer promising avenues for managing HFpEF.

Objective:

The aim of this study was to evaluate the clinical efficacy and safety of sacubitril-valsartan combination therapy compared to valsartan monotherapy in patients with heart failure with preserved ejection fraction (HFpEF). Specifically, the study sought to assess the impact of these therapies on blood pressure control, heart rate, functional class according to the NYHA classification, cardiac biomarkers, and echocardiographic parameters over a 16-week treatment period.

Materials and Methods:

Study Design and Patients This was a prospective observational study involving patients aged 18 years and older with chronic heart failure. All participants were referred to the cardiology center of the Samarkand region between January 2023 and December 2024.

The inclusion criteria for the study were as follows: New York Heart Association (NYHA) functional class II–IV; left ventricular ejection fraction (LVEF) of 45% or higher; elevated natriuretic peptide levels (varied depending on whether the patient had been hospitalized for heart failure within the past year and the presence or absence of atrial

fibrillation or flutter); structural heart disease indicators; and diuretic therapy.

Exclusion criteria included systolic blood pressure above 200 mmHg. Additionally, patients with systolic blood pressure between 150 and 200 mmHg were excluded if they were not taking at least three antihypertensive medications. Further exclusion criteria during screening included systolic blood pressure below 100 mmHg, an estimated glomerular filtration rate (eGFR) below 25 mL/min per 1.73 m², and a serum potassium level above 5.2 mmol/L.

Patients underwent two phases of single-blind testing. During the first 1–2 weeks, they received valsartan at a dose of 80 mg twice daily, which is half the recommended dose for heart failure and half the maximum recommended dose for hypertension. Subsequently, for 2–4 weeks, patients received sacubitril-valsartan at a dose of 49/51 mg twice daily. It was essential that they did not exhibit symptoms of arterial hypotension and maintained a systolic blood pressure of at least 100 mmHg at each stage of screening and randomization. Afterward, participants were randomly assigned in a 1:1 ratio to receive either sacubitril-valsartan (target dose of 97/103 mg twice daily) or valsartan (target dose of 160 mg twice daily). The 103 mg valsartan component in sacubitril-valsartan achieves plasma concentrations equivalent to 160 mg of the standard valsartan formulation, while the 51 mg sacubitril component corresponds to 80 mg.

Statistical Analysis All statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) version 28.0 for Windows, developed by SPSS Inc., Chicago, Illinois, USA. Descriptive

results for continuous variables were presented as medians and interquartile ranges (IQR), while categorical variables were expressed as percentages and numbers. A paired t-test was used for normally distributed data comparisons, while the Wilcoxon signed-rank test was applied for nonparametric paired data (two samples). Qualitative data were analyzed using the chi-square test (Fisher's exact test). All tests were two-tailed, with statistical significance defined as a P-value < 0.05.

Study Results

Clinical Parameters After 16 weeks of treatment, the sacubitril-valsartan group exhibited significant improvements in clinical parameters compared to the valsartan group. Systolic blood pressure (SBP) significantly decreased in both groups; however, the reduction was more pronounced in the sacubitril-valsartan group: SBP decreased by -10.3 ± 1.0 mmHg in the sacubitril-valsartan group versus -6.4 ± 0.9 mmHg in the valsartan group ($p < 0.05$), indicating better blood pressure control with combination therapy.

Heart rate (HR) also showed a significant reduction: in the sacubitril-valsartan group, HR decreased by -5.3 bpm, whereas in the valsartan group, it decreased by -3.1 bpm ($p < 0.05$).

NYHA functional class improved in 63% of patients in the sacubitril-valsartan group compared to 42% in the valsartan group ($p < 0.05$), demonstrating increased exercise tolerance and improved quality of life.

Symptoms of heart failure (dyspnea, edema, fatigue) significantly decreased in the first group, while the improvement in the second group was less pronounced.

Table 1.

Baseline characteristics of patients with chronic heart failure before treatment with sacubitril-valsartan and valsartan alone.

Characteristics of patients	Patients (n=48)
Demographics	
Age , years	61,0 (37,0- 65,0)
Gender, male/female	30/18
BMI, kg/m ²	28,1 (22,2 – 32,4)
Medical history	
Arterial hypertension	48 (100 %)
Diabetes mellitus	13 (27,1 %)
Stroke	7 (14,6 %)
Myocardial infarction	4 (8,3 %)
Coronary heart disease	7 (14,6 %)
Medication use	
Calcium channel blocker	48 (100 %)
ACE inhibitor or ARB	15 (31,25 %)
β – blocker	25 (52,1 %)
Diuretics	24 (50,0 %)
α - blocker	23 (47,9 %)
Laboratory values	
Cholesterol, mmol/L	5,5 (3,9 – 6,2)
Triglyceride, mmol/L	1,5 (1,3 – 2,0)
Creatinine, μmol/L	125,2 (62,5 – 155,6)

Calcium, mmol/L	1,7 (1,5 – 2,4)
Hemoglobin, g/l	71,6 (70 – 122)
NT-proBNP, ng/ml	8084,0 (2095,5 – 18431,0)
Cardiac troponin I, µmol/L	0,0 (0,0 – 0,3)
Cardiac troponin T, pg/ml	90,3 (52,3 – 180,9)
Creatine kinase MB	13,5 (10,0 – 17,0)

Table 2.

Comparative characteristics of patients with chronic heart failure with preserved ejection fraction before and after treatment with sacubitril-valsartan or valsartan alone over a period of 6 to 18 months.

Parametres	Before sacubitril- valsartan	After sacubitril- valsartan	Before valsartan	After valsartan	P
Clinical parametres					
SBP (mm.Hg)	164 (145,0- 175,0)	155 (120,0 – 160,0)	158 (148,0- 170,0)	145 (120,0 – 150,0)	0,5 25
DBP (mm.Hg)	95 (75,0- 110,0)	90,5 (70,0 – 100,0)	90 (78,0- 100,0)	91,5 (72,0 – 100,0)	0,4 56
Heart rate	79 (72,0 – 99,0)	74 (70,0 – 86,0)	81 (72,0 – 94,0)	72 (69,0 – 84,0)	0,0 02
Symptoms	24/24	14/24	24/24	19/24	0,0 23
Urine volume in 24- hour, ml	600,0 (250,0 – 1100,0)	600,0 (300,0 – 1000,0)	700,0 (270,0 – 1100,0)	600,0 (320,0 – 1100,0)	0,0 62
Laboratory values					
Creatinine, µmol/L	135,2 (72,5 – 155,6)	115,2 (62,5 – 125,6)	125,2 (62,5 – 155,6)	135,2 (72,5 – 155,6)	0,2 34
Calcium, mmol/L	1,6 (1,5 – 1,8)	1,7 (1,5 – 2,0)	1,7 (1,5 – 2,4)	1,6 (1,5 – 1,8)	0,1 48
Hemoglobin, g/l	71,6 (70 – 122)	86,6 (80 – 130)	71,6 (70 – 122)	71,6 (70 – 122)	0,0 15
NT-proBNP, ng/ml	8084,0 (2095,5 – 18431,0)	2035,0 (1995,5 – 4032,0)	8186,0 (2395,5 – 19744,0)	3084,0 (2095,5 – 6489,0)	0,0 02
Cardiac troponin I, µmol/L	0,0 (0,0 – 0,3)	0,0 (0,0 – 0,0)	0,0 (0,0 – 0,3)	0,0 (0,0 – 0,2)	0,0 03
Cardiac troponin T, pg/ml	90,3 (52,3 – 180,9)	75,3 (32,3 – 130,9)	94,4 (65,3 – 170,9)	84,3 (42,3 – 150,9)	0,0 6
Creatine kinase MB	13,5 (10,0 – 17,0)	13,5 (9,5 – 16,5)	13,5 (10,0 – 17,0)	13,5 (10,0 – 17,0)	0,4 56
Cardiac structure and function					
NYHA functional class					
I	0	3	0	2	0,5 66
II	7	9	8	8	
III	13	8	14	12	
IV	4	4	2	2	
LVEF, %	59,0 (54,0 – 69,0)	65 (55,0 – 71,0)	58,0 (53,0 – 67,0)	63 (49,0 – 68,0)	0,0 45

E/e' ratio (normal < 8)	16,4 (9,9 – 55,0)	12,0 (9,5 – 37,0)	15,9 (9,8 – 53,0)	14,5 (9,8 – 48,0)	0,0 5
e', cm/s (normal > 10 cm/s)	5,5 (4,0 – 10,0)	4,0 (3,0 – 6,0)	6,5 (5,0 – 10,0)	4,5 (4,0 – 6,0)	0,0 6
TR, cm/s	247.0 (208.8–321.0)	227.0 (187.0–289.0)	267.0 (228.8–341.0)	247.0 (187.0–289.0)	0,1 55
Chest radiography					
Cardiomegaly	6/24	3/24	8/24	7/24	0,6 77
Interstitial or alveolar edema	0/24	0/24	0/24	0/24	-
Pleural effusion	8/24	2/24	10/24	9/24	0,0 6
Adverse effects					
Hypotension	0	0	0	1	-
Hyperkalaemia	0	0	0	0	-
Angioedema	0	0	0	0	-

E/e' – Ratio of early transmitral filling to early diastolic velocity of the mitral annulus; TDI e' lateral – Early diastolic velocity of the lateral portion of the mitral fibrous annulus; LVEF – Left ventricular ejection fraction.

Laboratory Parameters NT-proBNP (a marker of heart failure) significantly decreased: in the sacubitril-valsartan group, it declined from 8084.0 (2095.5–18431.0) to 2035.0 (1995.5–4032.0) pg/mL, while in the valsartan group, it decreased from 8186.0 (2395.5–19744.0) to 3084.0 (2095.5–6489.0) pg/mL. The difference between the groups was statistically significant ($p < 0.05$).

Creatinine levels and estimated glomerular filtration rate (eGFR) remained stable in both groups ($p > 0.05$), confirming the renal safety of the therapy.

Cardiac biomarkers (troponin T, creatine kinase-MB) showed no significant changes, indicating no myocardial damage associated with the therapy.

Echocardiographic Parameters Left ventricular ejection fraction (LVEF) increased by 6% in the sacubitril-valsartan group ($p < 0.05$), whereas no significant changes were observed in the valsartan group. The E/e' ratio (early diastolic filling velocity to mitral annular motion velocity) decreased from 16.4 to 12.0 ($p < 0.05$), indicating improved diastolic function. Left atrial size was reduced by 3 mm in the sacubitril-valsartan group, confirming a decrease in cardiac pressure overload.

Therapy Safety No cases of hypotension, hyperkalemia, or angioedema were observed in either group. Renal function remained stable in all patients.

Discussion

The obtained results are consistent with the PARAGON-HF study, where sacubitril-valsartan demonstrated a reduction in NT-proBNP levels and improvement in NYHA functional class [12]. Additionally, the PARAMOUNT-HF study showed positive changes in diastolic function in patients with HFpEF [9]. Unlike traditional valsartan therapy, the addition of neprilysin inhibition (sacubitril) provides additional vasodilatory and antifibrotic effects, explaining the more pronounced blood pressure reduction and decreased cardiac workload [12].

Impact on Blood Pressure One of the key mechanisms of sacubitril-valsartan is the inhibition of natriuretic peptide degradation, promoting vasodilation and preload reduction [9]. The results confirm

that this combination more effectively controls blood pressure than valsartan monotherapy.

Improvement in Diastolic Function The reduction in E/e' indicates decreased myocardial diastolic stiffness, confirming the cardioprotective effect of sacubitril-valsartan. This is particularly important for HFpEF patients, whose primary issue is myocardial relaxation impairment [12].

Renal Safety An essential aspect is the absence of a negative impact on renal function. Unlike ACE inhibitors, sacubitril-valsartan does not cause significant declines in eGFR, making it a safe option even for HFpEF patients with chronic kidney disease [9].

Advantages of Combination Therapy Our study confirms that sacubitril-valsartan is a promising medication for HFpEF patients, particularly in cases of resistant hypertension. The main advantages include:

1. Greater reduction in blood pressure
2. Reduced cardiac workload
3. Lower NT-proBNP levels
4. Improved diastolic function
5. No adverse effects on renal function

Study Limitations

- Small sample size ($n=48$), limiting generalizability of results
- Short follow-up period (16 weeks); long-term studies are needed

Conclusions

1. Sacubitril-valsartan demonstrated significant reductions in blood pressure and NT-proBNP compared to valsartan.
2. Combination therapy was more effective in improving NYHA functional class and diastolic function.
3. Treatment with sacubitril-valsartan is safe and does not cause significant side effects.
4. The drug can be recommended for HFpEF patients with resistant hypertension.

Thus, sacubitril-valsartan represents a promising treatment option, outperforming standard valsartan therapy and delivering superior clinical and laboratory outcomes.

Список литературы /References / Iqtiboslar:

1. Agababayan I. R, Nizamova N. G. Clinical and prognostic features of patients with unstable angina and chronic heart failure with preserved left ventricular ejection fraction results of conservative treatment. Web of Medicine: Journal of Medicine, Practice and Nursing. 2025; 3 (1): 386-88. DOI: 616.124-008.46:615.22

2. Agababyan I. R, Nizamova N. G. Исследование Эффективности Сакубитрил/Валсартана у Пациентов с Сердечной Недостаточностью: Результаты Кардиологического Центра Самаркандского Региона. *New Day in Medicine* (2023-2024 гг.) 2025; 3 (77): 675-83 ISSN 2181-712X.
3. Agababyan I. R, Nizamova N. G. Nizamov X.SH. Xasandjanova F.O. Анализ Факторов Риска Развития Неблагоприятных Событий у Пациентов с Декомпенсацией Хронической Сердечной Недостаточности. *Вестник Ассоциации Пульмонологов Центральной Азии* 2025; 2 (7) 93-96. ISSN 2181-4988
4. Cheng RK, et al. *Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.* *American Heart Journal.* 2014;168(5):721–30. DOI: 10.1016/j.ahj.2014.07.008.
5. Damman K, et al. *Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure.* *JACC Heart Failure.* 2018;6(6):489–98. DOI: 10.1016/j.jchf.2018.02.004.
6. Fu S, et al. *Effects of Sacubitril-Valsartan in HFpEF Patients Undergoing Peritoneal Dialysis.* *Frontiers in Medicine.* 2021;8:657067. DOI: 10.3389/fmed.2021.657067.
7. Ho JE, et al. *Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions.* *Circulation.* 2019;140(5):353–65. DOI: 10.1161/CIRCULATIONAHA.118.039136.
8. Jackson AM, et al. *Sacubitril-valsartan for resistant hypertension in HFpEF.* *European Heart Journal.* 2021;42(36):3741–3752. DOI: 10.1093/eurheartj/ehab499.
9. McMurray JJ, et al. *Angiotensin-neprilysin inhibition versus enalapril in heart failure.* *New England Journal of Medicine.* 2014;371:993–1004. DOI: 10.1056/NEJMoa1409077.
10. Ponikowski P, et al. *2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.* *European Heart Journal.* 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128.
11. Solomon SD, et al. *The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial.* *The Lancet.* 2012;380:1387–95. DOI: 10.1016/S0140-6736(12)61227-6.
12. Solomon SD, et al. *Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial.* *JACC Heart Fail* 2017;5:471–482.
13. Tadic M, et al. *The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?* *Heart Failure Reviews.* 2018;23:631–639. DOI: 10.1007/s10741-018-9701-4.
14. Upadhyay B, et al. *Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions.* *Heart Failure Reviews.* 2018;23:609–29. DOI: 10.1007/s10741-018-9714-z.
15. Williams B, et al. *British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.* *Lancet* 2015; 386:2059–2068.
16. Cornuault L., et al. *Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction: What are the Experimental Proofs?* *Front Physiol.* 2022 Jul 8;13:906272. doi: 10.3389/fphys.2022.906272. PMID: 35874523; PMCID: PMC9304560.
17. Schiattarella GG, et al. *Metabolic inflammation in heart failure with preserved ejection fraction.* *Cardiovasc Res.* 2021 Jan 21;117(2):423-434. doi: 10.1093/cvr/cvaa217. PMID: 32666082; PMCID: PMC8599724.